D acu-tt tfizitulujit n waṭṭan n ukansir n tgezzayt?
Tasnudert n tdawsa n ukunsir n tgezzayt tga azal i tmegrawin d yisenfaren i d-yettawin ɣer usnulfu d ufara n ukunsir n tgezzayt.
Aṭṭan n uksum ameqqran, yettwassen daɣen s yisem n uksum n tgezzayt, d yiwen n ṣṣenf n waṭṭan n uksum i d-ibeddun deg tgezzayt neɣ deg tgezzayt, d iferdisen n tgezzayt tameqqrant.
Yebda-d s umata d yiwen n uferḍas iwumi qqaren apulip, izemren ad yuɣal d akunsir s teɣzi n wakud.
Tasnudert n tdawsa n ukunsir n tgezzayt tettawi-d ɣef waṭas n yimgan, gar-asen ibeddilen ijenṭiyen, afulki d yimgan.
Imuttiyen ijenṭiyen zemren ad d-ilin deg DNA n yiɣsan n uksum, d ayen yettawin ɣer unefli d beṭṭu ur nettwaḥkem ara n yiɣsan.
Imuttiyen-a zemren ad ttwaṛebbin neɣ ad d-ilin, yerna zemren ad d-lhin d yijinaten yemgaraden i yettekkan deg unefli, deg beṭṭu akked useggem n tsilunin.
Asfuǧǧeɣ deg uksum ameqqran, i izemren ad d-yeglu s waṭṭanen am waṭṭan affiẓan n tgeẓẓal, yezmer daɣen ad yesnerni amihi n ukansir n uksum ameqqran.
Asfuǧǧeɣ arurad yezmer ad d-yawi ɣer usuffeɣ n yikamiyulen i yesnernayen amɣi d beṭṭu n tsilunin, ayen yezmer ad d-yawi ɣer usnulfu n kunsir.
Iseɣẓanen n twennaṭ, am učči, amek yettidir yiwen, d tuffɣa ɣer kra n yimɣan, zemren daɣen ad d-rnun ɣer unfafad bu uɛebbuḍ.
Tissit yeččuren d aksum azeggaɣ akked uksum yettwafeṣlen, amedya, tettwassen d akken tettmuddu amihi n ukansir n tgezzayt.
Llan daɣen kra n ssebbat nniḍen, am tuget n lmizan, ddexxan, d lexṣaṣ n waddal, i izemren ad ssemɣaren amihi.
Mi ara d-yebdu kan ukansir n tgezzayt, yezmer ad yeddu deg waṭas n tseddarin, seg ukansir deg tezwara-s i d-yettwaḥebsen kan ɣer tgezzayt ɣer tseddarin yugaren aya anda kansir yemgarad ɣer tamiwin-nniḍen n tfekka.
Izirigen n ukunsir zemren ad kecmen izerfan d yiẓuran iqerben, yerna zemren daɣen ad ttwazerɛen s unagraw n tneffaḥt neɣ s azamul n yidammen ɣer yimukan ibeɛden, am tasa neɣ afud.
Asafar n ukansir n teɣmest deg umata d ahil n temhelt, n tesnujjya, n takimit d tesnujjya s wazal, ɣef leḥsab n uswir d umkan n ukansir.
Tujjya d usemmiḍ zik d tasarut i usnerni n yigmaḍ, acku akunsir n tgezzayt yezmer ad yeḥlu s waṭas ma yettwaṭṭef deg tezwara-s.
Asekyed n tezdeg, am tmuɣli n teɣmert, yezmer ad iεiwen ad d-yaf akunsir n teɣmert deg tezwara-s, mi ara yili yeshel ad yettwaḥlu.
Vidal-Vanaclocha F: The liver prometastatic reaction of cancer patients: implications for microenvironment-dependent colon cancer gene regulation. Cancer Microenviron. 2011, 4 (2): 163-80.
Yagi T, Kubota E, Koyama H, Tanaka T, Kataoka H, Imaeda K, Joh T: Glucagon promotes colon cancer cell growth via regulating AMPK and MAPK pathways. Oncotarget. 2018, 9 (12): 10650-10664.
Sharma SH, Thulasingam S, Nagarajan S: Terpenoids as anti-colon cancer agents - A comprehensive review on its mechanistic perspectives. Eur J Pharmacol. 2017, 795 (): 169-178.
Keshk WA, Zineldeen DH, Wasfy RE, El-Khadrawy OH: Fatty acid synthase/oxidized low-density lipoprotein as metabolic oncogenes linking obesity to colon cancer via NF-kappa B in Egyptians. Med Oncol. 2014, 31 (10): 192.
Dongfeng D, An C, Shujia P, Jikai Y, Tao Y, Rui D, Kai T, Yafeng C, Jianguo L, Xilin D: Explanation of colon cancer pathophysiology through analyzing the disrupted homeostasis of bile acids. Afr Health Sci. 2014, 14 (4): 925-8.
Tammali R, Ramana KV, Srivastava SK: Aldose reductase regulates TNF-alpha-induced PGE2 production in human colon cancer cells. Cancer Lett. 2007, 252 (2): 299-306.
['Anfafad: amejjay']
['Asmel-a web yettunefk-d kan i yiswiyen n uselmed d usissen, ur d-yettak ara iwellihen imejjayen neɣ isefka udmawanen.']
['Isallen i d-yettunefken ur ilaq ara ad ttwasqedcen i usebded neɣ i usemḥi n kra n wugur n tezmert neɣ aṭṭan, yerna wid yettnadin ɣef yiwellihen imsujjiyen udmawanen yessefk ad ẓren amejjay yesɛan turagt.']
['Ttxil-k ẓer belli azeṭṭa amseddayan i d-yettaken tiririyin i tuttriwin, ur iṣeḥḥa ara mliḥ ma yella d ayen yerzan uḍḍun. D amedya, amḍan n yimdanen yettwaḍḍfen s kra n waṭṭan.']
['Ssutur dima ṛṛay n ṭṭbib-ik neɣ n kra n umejjay-nniḍen ara iwalmen ɣef waṭṭan-ik. Ɣur-k ad tḥeqreḍ ṛṛay n ṭṭbib amsadur neɣ ad tεeṭṭleḍ deg usuter-is ɣef lǧal n kra i teɣriḍ deg usmel-a. Ma tɣileḍ ahat tesεiḍ liḥala n tεeǧlanit deg tezmert, siwel 911 neɣ ṛuḥ ɣer texxamt n tεeǧlanit i d-iqerben. Ulac assaɣ gar ṭṭbib d umuḍin i d-yettnulfun s usmel-a neɣ aseqdec-is. BioMedLib neɣ ixeddamen-is, neɣ kra n win yettekkiyen deg usmel-a, ur d-ttaken ara yakk kra n yisumren, s wawal neɣ s usemres, ɣef ayen yerzan isallen i d-yettunefken dagi neɣ aseqdec-is.']
['Anekcum: azref n uḍfar']
['Asaḍuf n umeskar n yizerfan n wemdan n alfin (Digital Millennium Copyright Act) n 1998, 17 U.S.C. § 512 (DMCA) yettak-d ttawil i yimeskaren n yizerfan n wemdan i yumnen belli ayen i d-yettbanen deg Internet yettḍurru izerfan-nsen ddaw usaḍuf n umeskar n yizerfan n wemdan n Marikan. ']
['Ma tumneḍ s wul yelhan belli kra n taɣult neɣ taɣawsa yettwafken deg unermes-nneɣ neɣ deg yiqeddacen-nneɣ tegzem azref-ik n uḥraz, tzemreḍ (neɣ amsedday-ik) ad aɣ-d-tazneḍ izen akken ad nessuter asuffeɣ n taɣult neɣ n taɣawsa-nni, neɣ ad nessader tuqqna ɣer-s. ']
['Isental yessefk ad ttwazen s tira s yimayl (ẓer asebter "Contact" i tansa n yimayl).']
['DMCA teḥwaǧ isalli-inek n tukksa n yizerfan yettwanekṛen ad d-yeglu s yisallen-a: (1) asegzi n umahil yettwaḥerzen s yizerfan yettwanekṛen i d-yettwanekren; (2) asegzi n uḍris yettwanekren d yisallen ara aɣ-yeǧǧen ad d-naf uḍris-nni; (3) isallen n usiwel inek, ladɣa tansa-inek, uṭṭun n tilifun d tansa imayl; (4) awal sɣur-k d akken tumneḍ s wayen yelhan belli aḍris-nni s wamek i d-tettcetkiḍ ur yettwasemres ara sɣur bab n yizerfan, neɣ amesten-is, neɣ s useqdec n kra n usaḍuf; ']
['(5) yiwet n tseddi sɣur-k, yettwatten s uḥasef n lekdeb, d akken isallen yellan deg uzenzi d iṣeḥḥan u tesεiḍ azref ad tesseḍruḍ izerfan umeskar i d-yeqqaren ttwarẓen; ']
['akked (6) azmul n tfekka neɣ n tuqqna tagensit n bab n yizerfan neɣ n umdan yettwafernen ad yexdem s yisem n bab n yizerfan. ']
['Ma ur d-terriḍ ara isallen-agi akk, yezmer ad d-yeglu s uεeṭṭel deg usefrek n ucetki-inek.']
['Assaɣ']
['Ttxil-k azen-aɣ-d imayl ma tesεiḍ asteqsi / asumer.']
What is pathophysiology of colon cancer?
The pathophysiology of colon cancer refers to the underlying mechanisms and processes that lead to the development and progression of colon cancer.
Colon cancer, also known as colorectal cancer, is a type of cancer that begins in the colon or rectum, which are parts of the large intestine.
It typically starts as a growth called a polyp, which can develop into cancer over time.
The pathophysiology of colon cancer involves several factors, including genetic mutations, inflammation, and environmental factors.
Genetic mutations can occur in the DNA of colon cells, leading to uncontrolled cell growth and division.
These mutations can be inherited or acquired, and they can affect various genes involved in cell growth, division, and repair.
Inflammation in the colon, which can be caused by conditions such as inflammatory bowel disease, can also increase the risk of colon cancer.
Chronic inflammation can lead to the release of chemicals that promote cell growth and division, potentially leading to the development of cancer.
Environmental factors, such as diet, lifestyle, and exposure to certain chemicals, can also contribute to the development of colon cancer.
A diet high in red and processed meats, for example, has been linked to an increased risk of colon cancer.
Other factors, such as obesity, smoking, and lack of physical activity, can also increase the risk.
Once colon cancer develops, it can progress through several stages, from early-stage cancer that is confined to the colon to more advanced stages where the cancer has spread to other parts of the body.
The cancer cells can invade nearby tissues and organs, and may also spread through the lymphatic system or bloodstream to distant sites, such as the liver or lungs.
Treatment for colon cancer typically involves a combination of surgery, chemotherapy, and radiation therapy, depending on the stage and location of the cancer.
Early detection and treatment are key to improving outcomes, as colon cancer is often curable when caught in its early stages.
Regular screening, such as colonoscopy, can help detect colon cancer at its earliest stages, when it is most treatable.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Ɣef']
['BioMedLib yesseqdac iselkimen imseddayen (algoritmes n ulmad n tnaεurt) i usnulfu n tuqqniwin n tuttriwin d tririyin.']
['Nebda s 35 imelyan n teẓrigin n tesnujjya tameddurt n PubMed/Medline. Rnu daɣen, isebtar n web n RefinedWeb.']
